Why carry out this study?

In the phase 3 PIONEER programme, oral semaglutide demonstrated efficacy versus placebo and most active comparators in achieving glycaemic control and body weight loss, with a safety profile consistent with the glucagon-like peptide-1 receptor agonist drug class.

Real-world data on the use of oral semaglutide in clinical practice are lacking. The PIONEER REAL programme is investigating the use of oral semaglutide in the real-world setting in 13 countries worldwide.

As part of this programme, the non-interventional PIONEER REAL Switzerland study assessed clinical outcomes associated with the once-daily use of oral semaglutide initiated within routine clinical practice in adults with type 2 diabetes in Switzerland.

What was learned from the study?

Participants treated with oral semaglutide in routine clinical practice in Switzerland experienced clinically significant improvements in glycaemic control and body weight, with a safety profile consistent with that reported in phase 3 trials.

The findings of PIONEER REAL Switzerland complement the results of the phase 3 PIONEER programme and support the use of oral semaglutide in a real-world setting.